Dr. Reddy's Laboratories announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U. S.

Food and Drug Administration (USFDA).

The Zyban brand and generic had U. S. sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health.

Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)